文献速递胸部肿瘤放疗

与III期非小细胞肺癌接受治疗及治疗意图相关的医疗系统因素:安大略省基于人群的研究

Health care system factors associated with receipt of treatment and treatment intent in stage III non-small cell lung cancer: A population-based study in Ontario.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-10-10

该研究基于加拿大安大略省2010至2018年健康行政数据,纳入7093例III期非小细胞肺癌患者,采用多因素逐步泊松回归分析医疗系统因素与接受治疗及治疗意图的关联。调整分析中未发现与是否接受治疗相关的医疗系统因素,而居住地区是与姑息性治疗意图相关的主要因素(RR范围0.88至1.67,P<0.001)。随时间推移治愈性治疗及先进放疗技术和免疫治疗的使用增加,但治疗意图的地区差异持续存在。

要点

  • 调整分析中未发现与是否接受治疗相关的医疗系统因素。
  • 居住地区是与姑息性治疗意图相关的主要医疗系统因素(RR范围0.88至1.67,P<0.001)。
  • 2010至2018年间治愈性治疗及先进放疗技术和免疫治疗使用增加,但治疗意图的地区差异持续存在。

核心结论

  • 居住地区是与III期非小细胞肺癌治疗意图相关的主要医疗系统因素,且该差异在放疗和全身治疗进展被采用后仍然存在。
  • 作者认为,解决无法解释的地区差异可能为改善治疗结局提供机会。

研究设计与样本

  • 基于人群的回顾性队列研究,使用加拿大安大略省2010至2018年健康行政数据,纳入年龄≥20岁、AJCC第7或第8版III期非小细胞肺癌患者。
  • 采用多因素逐步泊松回归模型,调整患者、疾病和治疗因素,分析医疗系统因素与接受治疗及治疗意图的关联。

主要发现

  • 共识别2010至2018年间7093例III期非小细胞肺癌患者。
  • 调整分析中,未发现与接受治疗 versus 未接受治疗相关的医疗系统因素。
  • 与姑息性治疗意图相关的主要医疗系统因素为居住地区(RR范围0.88至1.67,P<0.001)。
  • 按治疗年代分层(2010-2012 vs. 2013-2015 vs. 2016-2018),治愈性治疗接受率及先进放疗技术和免疫治疗使用随时间增加,但治疗意图的地区差异相似。

关键数值与推荐

  • 与姑息性治疗意图相关的居住地区相对风险(RR)范围为0.88至1.67,P<0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease, with a spectrum of anatomic extent, health status, and treatment approaches. Receipt of treatment and its intent should be independent of health system factors where care quality is optimal. We investigated the degree that modifiable health system factors are associated with receipt of treatment and treatment intent in stage III NSCLC in a large, universal health system. METHODS: This was a population-based, retrospective cohort study with health administrative data from Ontario, Canada, 2010-2018 for those aged ≥ 20 years, with AJCC 7 or 8 stage III NSCLC. We explored health system factors associated with NSCLC treatment: region of residence, diagnostic interval, travel distance, advanced radiation (e.g. IMRT, VMAT) and systemic therapy treatment volumes, and year of treatment (treatment era). The relative risk (RR) of (1) any treatment versus no treatment, and (2) palliative versus non-palliative treatment was determined, using multivariable stepwise Poisson regression models. We adjusted for patient, disease, and treatment factors. RESULTS: We identified 7,093 people with stage III NSCLC between 2010 and 2018. There were no health system factors associated with receipt of treatment versus no treatment in adjusted analysis. The major health system factor associated with palliative intent was region of residence (RR: Region ranges from 0.88 to 1.67, p < 0.001). Stratifying by era (2010-2012 vs. 2013-2015 vs. 2016-2018), there was an increase in receipt of curative treatment and use of advanced radiotherapy techniques and immunotherapy over time, but regional variation of treatment intent was similar. CONCLUSIONS: Region of residence emerged as the major health system factor associated with treatment intent for stage III NSCLC. This variation remained, even as advances in radiotherapy and systemic therapy were adopted. Our study suggests possible opportunities to improve care outcomes by addressing unexplained regional variation in care.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Thibodeau S, Nguyen P, Robinson A, et al. Health care system factors associated with receipt of treatment and treatment intent in stage III non-small cell lung cancer: A population-based study in Ontario. Clin Transl Radiat Oncol. 2024. PMID: 39677000. doi:10.1016/j.ctro.2024.100873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。